Axovant Sciences (AXON) PT Lowered to $25 at Cowen; Lewy Body Program Remains Focus

Axovant Sciences (AXON) PT Lowered to $9 at Evercore ISI

Evercore ISI analyst Josh Schimmer lowered his price target on Axovant Sciences (NASDAQ: AXON) to $9.00 (from $30.00) while maintaining an Outperform rating after MINDSET Trial Fails

Axovant Sciences (AXON) PT Lowered to $19 at JMP Securities

JMP Securities lowered its price target on Axovant Sciences (NASDAQ: AXON) to $19.00 (from $36.00) while maintaining a Market Outperform rating.

Analyst Jason Butler cites the ngative MINDSET results. The analyst comments "We have removed all value for intepirdine from our... More

UPDATE: Piper Jaffray Downgrades Axovant Sciences (AXON) to Neutral

(Updated - September 26, 2017 11:02 AM EDT)

(updated to add analyst comment)

Piper Jaffray downgraded Axovant Sciences (NASDAQ: AXON) from Overweight to Neutral with a price target of $9.00 (from $32.00).

Analyst Charles Duncan says the pipeline needs to be rebuild... More

Oppenheimer Downgrades Axovant Sciences (AXON) to Perform

Oppenheimer downgraded Axovant Sciences (NASDAQ: AXON) from Outperform to Perform.

For an analyst ratings summary and ratings history on Axovant Sciences click here. For more ratings news on Axovant Sciences click here.

Shares of Axovant Sciences closed at $24.25 yesterday.

UPDATE: Axovant Sciences (AXON) PT Lowered to $3 at Chardan Capital Markets

(Updated - September 26, 2017 9:52 AM EDT)

(updated to add comments)

Chardan Capital Markets lowered its price target on Axovant Sciences (NASDAQ: AXON) to $3.00 (from $8.00) while maintaining a Sell rating after the company fails to demonstrate statistical significance on either co-primary endpoint (ADAS-Cog and ADCS-ADL) in the phase III MINDSET trial of intepirdine in mild-to-moderate... More

Top five unique options volume: AMAT EFX NKE AXON GE

Top five unique options volume: AMAT EFX NKE AXON GE

Baird Downgrades Axovant Sciences (AXON) to Neutral, $6 PT

Baird downgraded Axovant Sciences (NASDAQ: AXON) from Outperform to Neutral with a price target of $6.00 (from $29.00) after the failure of the Phase 3 MINDSET study in Alzheimer's.

Analyst Brian Skorney commented, " There may be a reasonable argument to allow thesis drift here, given the... More

Axovant (AXON) Says its Intepirdine Phase 3 MINDSET Trial in AD Did Not Meet its co-Primary Efficacy Endpoints

Axovant Sciences (NASDAQ: AXON) today announced that the Phase 3 MINDSET clinical trial of its investigational drug intepirdine in patients with mild to moderate Alzheimer's disease (AD) who were receiving background donepezil therapy did not meet its co-primary efficacy endpoints. At 24 weeks, patients treated with 35 mg of intepirdine did not experience improvement in cognition or in measures of activities of daily living as measured by the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) and by the Alzheimer's Disease Cooperative Study-Activities of Daily Living scale (ADCS-ADL), respectively, compared to patients treated with placebo. In the study, intepirdine was... More